Metoprolol, one of the most commonly prescribed beta-blockers worldwide, can cause several types of eye-related side effects, though most are mild and serious problems are rare. The best-documented ocular effect is reduced tear production, which can lead to dry, irritated eyes. Beyond dryness, metoprolol has measurable effects on eye pressure, can occasionally trigger visual disturbances, and interacts with corneal tissue in ways that matter if you’re also using eye drops. The picture is more nuanced than a simple yes-or-no, and your individual risk depends on dose, other medications, and pre-existing eye conditions.
How Metoprolol Reduces Tear Production
Your lacrimal glands, which produce tears, are partly regulated by beta-adrenergic receptors. When metoprolol blocks these receptors, your eyes may produce fewer tears. Research examining systemic (injected) beta-blockers found that both selective beta-1 blockers like metoprolol and non-selective blockers significantly decreased tear production, though there were differences in how much each drug reduced output.1PubMed. Influence of topical and systemic beta-blockers on tear production Earlier experimental work showed that metoprolol blocked the natural facilitation of tear flow, supporting the idea that beta-1 receptors are directly involved in how much tear fluid your eyes release.2PubMed. Inhibition and facilitation of lacrimal flow by beta-adrenergic drugs
Metoprolol is classified as beta-1 selective, meaning it preferentially targets the receptors concentrated in the heart rather than the beta-2 receptors found in the lungs and, to some degree, in the lacrimal glands. In theory, this selectivity should spare tear production. In practice, selectivity is dose-dependent. At higher doses, metoprolol starts blocking beta-2 receptors too, and the protective advantage narrows. The research on systemic beta-blockers confirmed this: even selective beta-1 blockers decreased tear output at high doses because their selectivity effectively disappeared.1PubMed. Influence of topical and systemic beta-blockers on tear production
If you already have dry eyes, wear contact lenses, or spend long hours staring at screens, this effect could compound your symptoms. The dryness from metoprolol tends to be subtle rather than dramatic, so you might not immediately connect gritty, irritated eyes to your blood pressure medication. Preservative-free artificial tears can help manage mild cases, but if the discomfort is persistent, it’s worth mentioning to your prescriber, since switching to a different antihypertensive class could resolve the issue entirely.
Effects on Eye Pressure
Beta-blockers have a well-established role in lowering intraocular pressure (IOP), which is why timolol eye drops are a mainstay of glaucoma treatment. Oral metoprolol produces the same kind of pressure-lowering effect, even though it’s taken as a pill for the heart. In a pilot study of patients with glaucoma, oral metoprolol brought average IOP down from about 30 mmHg to roughly 21 mmHg, a drop the researchers considered large enough to be clinically meaningful.3PubMed. The effect of metoprolol on intra-ocular pressure in glaucoma. A pilot study The pressure rose again once the drug was stopped, confirming the reduction was drug-related.
This effect isn’t limited to people who already have elevated eye pressure. In people with normal IOP, a single oral dose of either metoprolol or propranolol produced a statistically significant decrease in eye pressure, with no meaningful difference between the two drugs.4PubMed. Effect of a single oral dose of propranolol or metoprolol on the intraocular pressure of persons without glaucoma
For most people taking oral metoprolol for hypertension or heart rhythm problems, this mild IOP-lowering effect is harmless or even slightly beneficial. The scenario that deserves attention is when you’re already using glaucoma medications that lower eye pressure, particularly timolol or another beta-blocker eye drop. The combination can produce an additive pressure drop that might push IOP lower than intended, and very low eye pressure carries its own risks, including reduced blood perfusion to the optic nerve. If you use both an oral beta-blocker and glaucoma drops, your ophthalmologist and cardiologist should be aware of each other’s prescriptions.
Visual Hallucinations and CNS-Related Visual Symptoms
Among the more alarming potential side effects of metoprolol are visual hallucinations, though they are genuinely rare. Metoprolol has an intermediate level of lipophilicity, a property that determines how easily a drug crosses from the bloodstream into fatty tissues like the brain. Highly lipophilic beta-blockers such as propranolol cross into the brain readily and produce more central nervous system side effects; hydrophilic ones like atenolol barely penetrate at all. Metoprolol sits between these extremes.5Journal of Medical Case Reports. Metoprolol-induced visual hallucinations: A case series
Published case reports have described patients on metoprolol who experienced formed visual hallucinations, seeing objects or figures that weren’t there, with symptoms resolving after the drug was discontinued. These reports emphasize that despite metoprolol’s extremely widespread use, such cases remain uncommon. The same lipophilicity that allows some brain penetration can also contribute to more mundane visual complaints like blurred vision, vivid dreams, or a general sense of visual “fuzziness.” These milder disturbances are more frequently reported than frank hallucinations, though they still affect only a minority of users.
If you experience any unexpected visual changes after starting metoprolol or after a dose increase, bring it up with your doctor. The association can be confirmed by stopping or reducing the drug and watching whether symptoms resolve. In most reported cases, they do.
What Happens When Metoprolol Contacts the Cornea Directly
Most people take metoprolol as an oral tablet, but researchers have also tested it as an eye drop for glaucoma. Those studies reveal effects on the cornea that, while mostly relevant to topical use, offer insight into how the drug interacts with ocular tissue.
In a head-to-head trial comparing metoprolol 3% eye drops with timolol 0.5% drops in glaucoma patients, roughly 58% of patients on metoprolol reported a transient burning sensation versus 26% of those on timolol. Both groups showed signs of dry eye on objective tests, but metoprolol was clearly the harsher of the two on the eye’s surface.6PubMed. Timolol and metoprolol in glaucoma. A comparison of the ocular hypotensive effect, local and systemic tolerance A separate five-month follow-up study of metoprolol 3% eye drops in glaucoma patients found that a small number developed transient epithelial keratopathy, mild damage to the outermost corneal layer, and one patient had a worsening visual field defect.7Acta Ophthalmologica. Metoprolol eyedrops 3%, a short-term comparison with pilocarpine and a five-month follow-up study
Laboratory work comparing the cytotoxicity of eight different beta-blockers on human corneal epithelial cells and retinal pigment epithelial cells found large differences in toxicity between drugs, roughly 60-fold across the group. The damage mechanism wasn’t specific to any one cell type, meaning the cornea wasn’t singled out for harm compared to other tissues.8Toxicology in Vitro. In vitro cytotoxicity of eight beta-blockers in human corneal epithelial and retinal pigment epithelial cell lines: comparison with epidermal keratinocytes and dermal fibroblasts The practical implication: beta-blockers vary widely in their potential to irritate ocular tissue, and the choice of which drug to use as an eye drop matters.
For oral metoprolol users, these corneal findings are mostly academic. The drug reaches the eye through the bloodstream at far lower concentrations than a topical drop delivers. But they do explain why metoprolol never gained traction as a glaucoma eye drop, despite its genuine IOP-lowering ability. Timolol proved both more effective at lowering pressure and better tolerated on the eye’s surface.
How Metoprolol Stacks Up Against Other Beta-Blockers
Your risk of eye-related side effects from a beta-blocker depends on which one you take. The two properties that matter most are receptor selectivity and lipophilicity.
On the dry-eye front, non-selective beta-blockers like propranolol and timolol block both beta-1 and beta-2 receptors at any dose, so they tend to suppress tear production more consistently. Metoprolol’s beta-1 selectivity offers some protection at lower doses, though that advantage erodes as the dose climbs.1PubMed. Influence of topical and systemic beta-blockers on tear production
For pressure lowering, topical timolol outperformed topical metoprolol by about 7 to 9 percent in a controlled crossover study, and a greater proportion of eyes reached the target IOP under timolol.6PubMed. Timolol and metoprolol in glaucoma. A comparison of the ocular hypotensive effect, local and systemic tolerance This is why timolol became the beta-blocker of choice for glaucoma, not because metoprolol doesn’t lower pressure, but because timolol does it better with less local irritation.
For CNS-related visual symptoms like hallucinations and vivid dreams, the ranking follows lipophilicity. Propranolol, the most fat-soluble of the common beta-blockers, carries the highest risk. Metoprolol falls in the middle. Atenolol, which barely crosses into the brain, carries the lowest risk. If you’re experiencing visual disturbances on metoprolol and need to stay on a beta-blocker, switching to atenolol is a reasonable discussion to have with your doctor.
On the reassuring side, animal studies looking specifically at blood flow to the eye found that metoprolol had no measurable effect on pulsatile ocular blood flow, suggesting it doesn’t starve the eye of blood supply the way some other medications might.9Drug Development Research. Effects of antiglaucoma drugs on ocular blood flow in ocular hypertensive rabbits
Recognizing and Managing Metoprolol-Related Eye Symptoms
The tricky part of connecting eye symptoms to metoprolol is timing. Dry eyes develop gradually, and most people attribute them to aging, screen use, or allergies before considering their medication. A few patterns can help you spot the connection:
- Onset after starting or increasing the dose: If dry eye symptoms appeared or worsened within weeks of beginning metoprolol or moving to a higher dose, the drug is a plausible contributor.
- Bilateral and persistent dryness: Allergic or environmental dry eye often fluctuates with exposure. Drug-induced dryness tends to be constant and affects both eyes equally.
- Visual changes without structural explanation: If your ophthalmologist examines your eyes and finds no cataracts, retinal problems, or refractive changes to explain blurred vision, medication side effects belong on the differential.
Artificial tears are the first-line management for mild drug-induced dry eye. Preservative-free formulations are preferable if you’re using them more than a few times a day, since preservatives like benzalkonium chloride can worsen corneal surface irritation over time. For people with moderate-to-severe dryness, a conversation about switching medications is more practical than layering on lubricants indefinitely.
Visual hallucinations or dramatic visual disturbances warrant a more urgent conversation with your prescriber. These symptoms, while rare, tend to resolve within days of stopping the drug. Your doctor may substitute a hydrophilic beta-blocker, switch to a different class of blood-pressure medication entirely, or adjust the dose downward.
What Pharmacovigilance Data Shows
Post-marketing surveillance gives a broader picture of metoprolol’s side-effect profile than any individual clinical trial can. An analysis of the FDA’s Adverse Event Reporting System (FAERS) identified over 16,800 reports associated with metoprolol, spanning hundreds of distinct adverse events across 23 organ-system categories.10Expert Opinion on Drug Safety. Metoprolol adverse events and literature analyses: case/non-case analyses using the FDA Adverse Event Reporting System (FAERS) Eye-related events represent a relatively small fraction of total reports, which is consistent with what clinical trials suggest: ocular side effects occur but are not among the drug’s most common problems. Cardiac, neurological, and gastrointestinal complaints dominate the reporting landscape.
Pharmacovigilance data has known limitations. Reports are voluntary and subject to under-reporting, and they cannot prove causation on their own. Still, the presence of ocular events in a large safety database confirms that these are recognized effects, not just theoretical possibilities from laboratory studies.
Glaucoma Patients on Oral Metoprolol
If you have glaucoma, the interplay between oral metoprolol and your eye medications deserves specific attention. The most common scenario involves a patient already on timolol eye drops who then gets prescribed oral metoprolol for a heart condition. Both drugs lower eye pressure, and both suppress the same beta-adrenergic pathways. The concern isn’t just that pressure might drop too low; it’s also that the oral beta-blocker partially saturates the same receptors the eye drops are trying to target, potentially reducing the drops’ additional benefit.
A related concern is additive effects on tear production. Timolol drops are already known to cause dry eye, and adding systemic metoprolol compounds that. In the crossover trial comparing the two drugs as topical agents, both metoprolol and timolol groups showed objective signs of dry eye, including changes in tear break-up time and positive staining tests.6PubMed. Timolol and metoprolol in glaucoma. A comparison of the ocular hypotensive effect, local and systemic tolerance Combining a topical and an oral beta-blocker could amplify these surface effects.
If you’re in this situation, your ophthalmologist may consider switching your glaucoma drops to a non-beta-blocker class, such as a prostaglandin analog, which lowers IOP through a completely different mechanism and won’t overlap pharmacologically with your oral metoprolol. The key is making sure both specialists know what the other has prescribed.
Contact Lens Wearers and Metoprolol
Contact lens comfort depends heavily on a stable, adequate tear film. Anything that reduces tear volume or changes tear composition can make lenses feel dry, blurry, or uncomfortable within hours of insertion. Because metoprolol reduces tear output through its beta-receptor blockade, contact lens wearers are a group that may notice the effect sooner and more acutely than others.
Soft lenses are particularly sensitive to marginal tear production because they absorb water from the tear film to maintain their shape. If tear volume drops, the lens dehydrates slightly and tightens on the cornea, causing discomfort and reduced oxygen delivery. Rigid gas-permeable lenses are less affected by tear volume but depend on a smooth tear layer for optical clarity, so reduced tears can cause intermittent blurriness.
If you’ve worn contacts comfortably for years and suddenly find them intolerable after starting metoprolol, try rewetting drops compatible with your lens type before assuming you need to abandon contacts altogether. If rewetting drops aren’t enough, reducing wearing time or switching to daily disposable lenses with higher water content can help. These measures may buy enough comfort to make staying on metoprolol feasible. For some people, though, the combination of metoprolol and contact lenses simply doesn’t work, and that trade-off is worth discussing with your prescriber if contacts are important to your daily life.